Eli Lilly's Market Share Declines as Novo Nordisk Remains Steady in India
Eli Lilly's market share in India's weight-loss drug market dropped to 56% in March from 61% in February, while Novo Nordisk maintained its 25% share. The decline follows the launch of 26 generic brands of semaglutide by Indian drugmakers, which directly compete with Novo Nordisk's Ozempic and Wegovy.